Organometallic compounds are suitable for rational drug design[1] and have been considered as promising alternatives in cancer drug research[2].Especially half-sandwich Arene-Ruthenium(Ⅱ)compounds exhibited potency in anticancer activities[3].The complexes containing 9-aminoacridine have shown the interesting antimalarial and anticancer activities,where the 9-aminoacridine works as DNA topoisomerase Ⅱ inhibitors.[4-5] Herein,we reported a novel arene-Ruthenium(Ⅱ)complex involving 9-aminoacridine functional group.The single crystal structure has been resolved as listed in Fig.1 and the complex shown much lower cytotoxicity to L02 normal cells than A549 cancer cells.A further study of biological activity and anticancer mechanism of the listed complex are undergoing.